Pulmonary Cell News Volume 12.46 | Nov 23 2023

    By
    Laurisa Dohm
    -
    0
    9








    2023-11-22 | PULCN 12.46


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 12.46 – 23 November, 2023
    TOP STORY

    Inhalable Textile Microplastic Fibers Impair Airway Epithelial Differentiation

    Researchers used human and murine alveolar and airway-type organoids as well as air-liquid interface cultures derived from primary lung epithelial progenitor cells and incubated these with either nylon or polyester fibers or nylon leachate.
    [American Journal Of Respiratory And Critical Care Medicine]

    Abstract
    Request a free wallchart for a quick reference on growing organoids from stem cells.
    PUBLICATIONSRanked by the impact factor of the journal

    Inhaled Pulmonary Surfactant Biomimetic Liposomes for Reversing Idiopathic Pulmonary Fibrosis through Synergistic Therapeutic Strategy

    Inspired by the successful application of pulmonary surfactant (PS) replacement therapy in lung disease treatment, the authors developed PS nano-biomimetic liposomes to utilize its natural transport pathway for targeting AECs while reducing lung tissue clearance.
    [Biomaterials]

    Abstract

    Age-Associated H3K9me2 Loss Alters the Regenerative Equilibrium between Murine Lung Alveolar and Bronchiolar Progenitors

    Investigators reported that histone H3 lysine 9 di-methylation (H3K9me2), mediated by the methyltransferase G9a, regulated the dynamics of distal lung epithelial progenitor cells and that this regulation deteriorated with age.
    [Developmental Cell]

    AbstractGraphical Abstract

    Epigenetic Reprogramming Drives Epithelial Disruption in COPD

    Scientists sought to determine if epigenetic reprogramming of the cell-cell adhesion molecule E-cadherin disrupted epithelial integrity, and if by reducing these epigenetic marks, they could restore epithelial integrity and rescue alveolar airspace destruction.
    [American Journal Of Respiratory Cell And Molecular Biology]

    Abstract

    Type I Interferon Signaling Induces a Delayed Antiproliferative Response in Respiratory Epithelial Cells during SARS-CoV-2 Infection

    The authors reported a high-throughput CRISPR screen for host genetic modifiers of the survival and proliferation of SARS-CoV-2-infected Calu-3 respiratory epithelial cells.
    [Journal Of Virology]

    Full Article

    Cancer Organoid-Based Diagnosis Reactivity Prediction (CODRP) Index-Based Anticancer Drug Sensitivity Test in ALK-Rearrangement Positive Non-Small Cell Lung Cancer (NSCLC)

    A drug sensitivity test was performed using patient-derived organoids from the patient tissue and the primary cancer characteristics of pateint-derived organoids were confirmed by pathological comparision with tissue slides.
    [Journal Of Experimental & Clinical Cancer Research]

    Full Article

    E3 Ligase Trim35 Inhibits LSD1 Demethylase Activity through K63-Linked Ubiquitination and Enhances Anti-Tumor Immunity in NSCLC

    Combinational use of a lysine-specific histone demethylase 1A (LSD1) inhibitor and anti-PD-1 therapy could significantly eradicate poorly immunogenic lung cancer with low Trim35.
    [Cell Reports]

    Full ArticleGraphical Abstract

    The Long Non-Coding RNA TAZ-AS202 Promotes Lung Cancer Progression via Regulation of the E2F1 Transcription Factor and Activation of Ephrin Signaling

    Researchers ientified and characterized a novel lncRNA, TAZ-AS202, expressed from the TAZ genomic locus and exerting pro-oncogenic functions in NSCLC.
    [Cell Death & Disease]

    Full Article

    IL-17A Promotes Tumorigenesis and Upregulates PD-L1 Expression in Non-Small Cell Lung Cancer

    The function of interleukin-17A (IL-17A) was examined in vitro by wound healing, migration, invasion, plate colony formation, and T cell killing assay.
    [Journal Of Translational Medicine]

    Full Article
    An ISSCR 2022 Innovation Showcase Webinar: Reliable In Vitro Culture Solutions for Your Alveolar Research, presented by Dr. Johanna Finn. Click to Watch Now.
    REVIEWS

    FOXO1, a Tiny Protein with Intricate Interactions: Promising Therapeutic Candidate in Lung Cancer

    The authors focus on the signaling pathways, and molecular mechanisms involved in FOXO1 regulation in lung cancer, and discuss pharmacological compounds that are currently being administered for lung cancer treatment by affecting FOXO1.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Bristol Myers’ $4.1B Turning Point Buy Yields FDA Approval for Lung Cancer Drug Augtyro

    The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer patients whose tumors have ROS1 oncogenic fusions.
    [Fierce Pharma]

    Editorial
    FEATURED EVENT

    9th International Conference on Mechanics of Biomaterials and Tissues

    December 16 – 20, 2023
    Waikoloa Beach, Hawaii, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Host-Pathogen Interactions in the Human Lung

    Rutgers Health – Newark, New Jersey, United States

    Postdoctoral Fellow – iPSC Lung Disease Models

    Royal College of Surgeons in Ireland – Dulin, Ireland

    Postdoctoral Fellowships – Cancer Research

    NIH National Cancer Institute – Bethesda, Maryland, United States

    Tenure Track Faculty – Cancer and Cellular Biology

    Temple University – Philadelphia, Pennsylvania, United States

    Postdoctoral Research Associate – Genetics and Genomics of Lung Disease

    National Jewish Health – Denver, Colorado, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2